Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Share-based Compensation (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Share-based Compensation for 2 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 93.27% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, up 7.85% year-over-year, with the annual reading at $6.9 million for FY2025, 7.85% up from the prior year.
  • Share-based Compensation hit $2.9 million in Q4 2025 for Xilio Therapeutics, up from $1.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.9 million in Q4 2025 to a low of $1.1 million in Q3 2025.